Department of Pharmacy, Tripura University, Suryamaninagar-799022, India.
Curr Drug Discov Technol. 2022;19(3):e140222201110. doi: 10.2174/1570163819666220214115408.
The self-association of DNA formed by Hoogsteen hydrogen bonding comprises several layers of four guanine or G-tetrads or G4s. The distinct feature of G4s, such as the G-tetrads and loops, qualify structure-selective recognition by small molecules and various ligands and can act as potential anticancer therapeutic molecules. The G4 selective ligands can influence gene expression by targeting a nucleic acid structure rather than sequence. Telomere G4 can be targeted for cancer treatment by small molecules inhibiting the telomerase activity, whereas c-MYC is capable of controlling transcription and can be targeted to influence transcription. The k-RAS is one of the most frequently encountered oncogenic driver mutations in pancreatic, colorectal, and lung cancers. The k-RAS oncogene plays an important role in acquiring and increasing drug resistance and can also be directly targeted by small molecules to combat k-RAS mutant tumors. Modular G4 ligands with different functional groups, side chains, and rotatable bonds, as well as conformation, affect the binding affinity/ selectivity in cancer chemotherapeutic interventions. These modular G4 ligands act by targeting the diversity of G4 loops and groves and assist in developing more drug-like compounds with selectivity. In this review, we present the recent research on synthetic G4 DNA-interacting ligands as an approach towards the discovery of target-specific anticancer chemotherapeutic agents.
由 Hoogsteen 氢键形成的 DNA 自缔合包括几层四个鸟嘌呤或 G-四联体或 G4。G4 的独特特征,如 G-四联体和环,使小分子和各种配体具有结构选择性识别的能力,并可以作为潜在的抗癌治疗分子。G4 选择性配体可以通过靶向核酸结构而不是序列来影响基因表达。可以通过抑制端粒酶活性的小分子靶向端粒 G4 进行癌症治疗,而 c-MYC 能够控制转录,并可以靶向影响转录。k-RAS 是胰腺癌、结直肠癌和肺癌中最常见的致癌驱动突变之一。k-RAS 癌基因在获得和增加耐药性方面起着重要作用,并且可以通过小分子直接靶向来对抗 k-RAS 突变肿瘤。具有不同官能团、侧链和可旋转键以及构象的模块化 G4 配体,影响癌症化学治疗干预中的结合亲和力/选择性。这些模块化 G4 配体通过靶向 G4 环和凹槽的多样性来发挥作用,有助于开发更具选择性的类药化合物。在这篇综述中,我们介绍了合成 G4 DNA 相互作用配体的最新研究进展,作为发现靶向特定抗癌化疗药物的方法。